Tumour suppressive effects of WEE1 gene silencing in breast cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 11, 2013, Pages 6605-6611

  Ghiasi, Naghmeh ^a,c   Habibagahi, Mojtaba ^b   Rosli, Rozita ^c   Ghaderi, Abbas ^a,b   Yusoff, Khatijah ^c   Hosseini, Ahmad ^a   Abdullah, Syahrilnizam ^c   Jaberipour, Mansooreh ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Breast cancer; G2 arrest abrogation; ShRNA; Viability inhibition; WEE1

Indexed keywords

EID: 84892454696     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.11.6605     Document Type: Article

References (32)

1. Amundson SA, Myers TG, Fornace AJ (1998). Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene, 17, 3287-99.
2. Bridges KA, Hirai H, Buser CA, et al (2011). MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res, 17, 5638-48.
3. Bucher N, Britten CD (2008). G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer, 98, 523-8.
4. Canman CE, Gilmer TM, Coutts SB, et al (1995). Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev, 9, 600-11.
5. Carrassa L, Chila R, Lupi M, et al (2012). Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle, 11, 2507-17.
6. Castedo M, Perfettini JL, Roumier T, et al (2004). Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene, 23, 4362-70.
7. Chen PL, Chen YM, Bookstein R, et al (1990). Genetic mechanisms of tumor suppression by the human p53 gene. Science, 250, 1576-80.
8. Dixon H, Norbury CJ (2002). Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle, 1, 362-8.
9. Foulkes WD, Stefansson IM, Chappuis PO, et al (2003). Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst, 95, 1482-5.
10. Fujisawa T, Watanabe J, Kamata Y, et al (2003). VEGF expression and its reguration by p53 gene transfection in endometrial carcinoma cells. Hum Cell, 16, 47-54.
11. Gottlieb E, Haffner R, King A, et al (1997). Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiationinduced activation during embryogenesis. EMBO J, 16, 1381-90.
12. Gottlieb E, Oren M (1998). p53 facilitates pRb cleavage in IL- 3-deprived cells: novel pro-apoptotic activity of p53. EMBO J, 17, 3587-96.
13. Hirakawa S, Kodama S, Kunstfeld R, et al (2005). VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med, 201, 1089-99.
14. Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al (2005). The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer, 6, 391-401.
15. Igarashi M, Nagata A, Jinno S, et al (1991). Wee1(+)-like gene in human cells. Nature, 353, 80-3.
16. Iorns E, Lord CJ, Grigoriadis A, et al (2009). Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One, 4, 5120.
17. Jiang M, Milner J (2003). Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev, 17, 832-7.
18. Kelly PN, Strasser A (2011). The role of Bcl-2 and its prosurvival relatives in tumourigenesis and cancer therapy. Cell Death Differ, 18, 1414-24.
19. Lacroix M, Toillon RA, Leclercq G (2006). p53 and breast cancer, an update. Endocr Relat Cancer, 13, 293-325.
20. Lai Z, Ferry KV, Diamond MA, et al (2001). Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J Biol Chem, 276, 31357-67.
21. Mandal S, Berube G, Asselin E, et al (2007). A new platinum complex of triazine demonstrates G1 arrest with novel biological profile in human breast cancer cell line, MDAMB- 468. Bioorg Med Chem Lett, 17, 2139-45.
22. Mir SE, De Witt Hamer PC, Krawczyk PM, et al (2010). In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell, 18, 244-57.
23. Mukhopadhyay D, Tsiokas L, Sukhatme VP (1995). Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res, 55, 6161-5.
24. Murrow LM, Garimella SV, Jones TL, et al (2010). Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat 122, 347-57.
25. Pal S, Datta K, Mukhopadhyay D (2001). Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res, 61, 6952-7.
26. Porebska I, Wyrodek E, Kosacka M, et al (2006). Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer. In Vivo, 20, 599-604.
27. Prasad KA, Church JG (1997). EGF effects on p53 in MDA-468 human breast cancer cells: implications for G1 arrest. Cell Prolif, 30, 81-94.
28. Schlotter CM, Vogt U, Allgayer H, et al (2008). Molecular targeted therapies for breast cancer treatment. Breast Cancer Res, 10, 211.
29. Tibes R, Bogenberger JM, Chaudhuri L, et al (2012). RNAi screening of the kinome with cytarabine in leukemias. Blood, 119, 2863-72.
30. Venkatachalam S, Tyner SD, Pickering CR, et al (2001). Is p53 haploinsufficient for tumor suppression?. Implications for the p53+/- mouse model in carcinogenicity testing. Toxicol Pathol, 29, 147-54.
31. Vousden KH, Lu X (2002). Live or let die: the cell's response to p53. Nat Rev Cancer, 2, 594-604.
32. Wang Y, Decker SJ, Sebolt-Leopold J (2004). Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther, 3, 305-13.